APC, NIBRT Partner to Improve Access to Biopharmaceutical Services

Article

The partnership will enable the Applied Process Company (APC) and the National Institute for Bioprocessing Research & Training (NIBRT) to provide increased access to R&D and analytical services.

The Applied Process Company (APC) and the National Institute for Bioprocessing Research & Training (NIBRT) announced on April 2, 2019 that the companies signed a strategic partnership agreement to provide their respective client bases with increased access to R&D and analytical services across their complementary biopharmaceutical services. 

According to NIBRT, the partnership is expected to better serve the complex needs of the shared client base by leveraging APC’s process development and optimization services through application of its process analytical technology, combined with NIBRT’s extensive biopharmaceutical services and knowledge in single-use, pilot plant, and bioanalytical capabilities.

APC reports that it has been using NIBRT’s expertise to complement its own analytical development services in certain areas for several years. This agreement expands the companies’ partnership to offer their combined client base access to the broader complementary services.

“We welcome this logical extension to our current relationship with NIBRT and recognize the value of their biopharmaceutical services, complementing our own in-house bioprocess development and optimization technologies, which have recently benefited from multimillion-euro investment,” said APC Chief Commercial Officer David Downey, in a press release. “This mutually beneficial arrangement will further increase our capabilities in delivering complex process development solutions to our global client base.”  

“Our global client base has complex bioanalytical characterization and process development requirements to support their development of their innovative therapeutics,” said Killian O’Driscoll, director of projects at NIBRT, in the release. “We’re delighted to announce the further strengthening of our partnership with APC to assist clients design, develop, and characterize their biological processes and products.”

Source: NIBRT

Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2024 MJH Life Sciences

All rights reserved.